IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.453
NA - Nord America 3.024
SA - Sud America 1.466
EU - Europa 553
AF - Africa 114
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 9.621
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.069
US - Stati Uniti d'America 2.876
BR - Brasile 1.255
CN - Cina 556
VN - Vietnam 333
HK - Hong Kong 154
IT - Italia 125
GB - Regno Unito 93
AR - Argentina 87
CA - Canada 63
MX - Messico 63
DE - Germania 62
BD - Bangladesh 57
IN - India 56
ZA - Sudafrica 54
EC - Ecuador 44
FR - Francia 34
IQ - Iraq 31
PL - Polonia 30
ID - Indonesia 29
ES - Italia 23
TR - Turchia 23
RU - Federazione Russa 22
JP - Giappone 21
NL - Olanda 21
UA - Ucraina 21
FI - Finlandia 20
SE - Svezia 20
PK - Pakistan 16
PY - Paraguay 16
MA - Marocco 15
UY - Uruguay 15
CO - Colombia 14
CZ - Repubblica Ceca 14
UZ - Uzbekistan 14
EG - Egitto 13
LT - Lituania 13
CL - Cile 11
AE - Emirati Arabi Uniti 10
IE - Irlanda 10
KE - Kenya 9
VE - Venezuela 9
AT - Austria 8
DZ - Algeria 8
SA - Arabia Saudita 8
CH - Svizzera 7
KR - Corea 7
PE - Perù 7
TN - Tunisia 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
JM - Giamaica 6
JO - Giordania 6
KZ - Kazakistan 6
NP - Nepal 6
PS - Palestinian Territory 6
AZ - Azerbaigian 5
IL - Israele 5
OM - Oman 5
AU - Australia 4
BE - Belgio 4
GR - Grecia 4
LB - Libano 4
PH - Filippine 4
TT - Trinidad e Tobago 4
AL - Albania 3
LK - Sri Lanka 3
MD - Moldavia 3
NG - Nigeria 3
TH - Thailandia 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
EE - Estonia 2
GY - Guiana 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
KW - Kuwait 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GT - Guatemala 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
MM - Myanmar 1
MY - Malesia 1
Totale 9.616
Salva come PNG Salva come JPEG
Città #
Singapore 941
The Dalles 840
Dallas 444
Shanghai 334
Ashburn 312
Beijing 157
Hong Kong 149
Ho Chi Minh City 131
São Paulo 113
Boardman 96
Santa Clara 82
Hanoi 71
Los Angeles 64
New York 50
Rio de Janeiro 43
Seattle 40
Belo Horizonte 35
Johannesburg 32
Chandler 29
Mexico City 29
Brasília 27
Warsaw 24
Milan 23
Chicago 22
Curitiba 21
Tokyo 21
London 20
Phoenix 20
Council Bluffs 19
Helsinki 19
Brooklyn 18
Guayaquil 18
Toronto 18
Boston 17
Campinas 17
Dhaka 17
Atlanta 16
Montreal 16
Ribeirão Preto 16
Porto Alegre 15
Quito 14
Stockholm 14
Ankara 13
Montevideo 13
Orem 13
San Francisco 13
Wilmington 13
Goiânia 12
Munich 12
Sorocaba 12
Tashkent 12
Cape Town 11
Caxias do Sul 11
Hải Dương 11
Manchester 11
Rome 11
Asunción 10
Charlotte 10
Dublin 10
Lauterbourg 10
Recife 10
Reston 10
Aracaju 9
Campo Grande 9
Denver 9
Haiphong 9
New Delhi 9
Poplar 9
Santos 9
Amsterdam 8
Baghdad 8
Bauru 8
Brno 8
Da Nang 8
Joinville 8
Mumbai 8
Paris 8
Salvador 8
Santo André 8
Volta Redonda 8
Biên Hòa 7
Cabo Frio 7
Cairo 7
Houston 7
Indaiatuba 7
Naples 7
Thái Nguyên 7
Amman 6
Assago 6
Can Tho 6
Córdoba 6
Erbil 6
Florianópolis 6
Juiz de Fora 6
Jundiaí 6
Kingston 6
Lawrence 6
Mauá 6
Nairobi 6
Nuremberg 6
Totale 4.910
Salva come PNG Salva come JPEG
Nome #
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer 173
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma 161
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 126
Morbidity And Complication Of Minimally Invasive Staging For Apparent Early-Stage Epithelial Ovarian Cancer: A Preliminary Analysis Of REMISSION Study 105
Pembrolizumab for locally advanced cervical cancer - Authors' reply 78
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 71
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 68
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 68
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey 65
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 60
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 59
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 54
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 52
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 51
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors 51
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? 51
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 48
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 48
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 47
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 46
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 45
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 43
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 42
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 42
"Tumori della vulva e della vagina" 41
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile 41
A critical assessment on the role of sentinel node mapping in endometrial cancer 40
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 40
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 40
Trabectedin as a chemotherapy option for patients with BRCA deficiency 40
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 39
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 39
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 39
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 39
TERAPIA PRIMARIA DEL CARCINOMA DELL'ENDOMETRIO: CHEMIOTERAPIA 38
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 37
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy 37
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer 36
Advances in laparoscopic surgery for cervical cancer 36
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) 36
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 36
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 36
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 35
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience 35
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment 35
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 35
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 35
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 35
Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case 35
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 34
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 34
Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity 34
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 34
Do you agree with populations that have been defined as 'noncandidates' to receiving platinum? 33
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 33
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 33
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study 33
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 33
Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study 33
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 33
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 32
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial 32
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 32
Peritoneal cytology as prognostic factor in cervical cancer 32
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 32
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 32
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer 32
Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses 32
Uterine serous carcinoma 32
Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? 31
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 31
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 31
Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers 31
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 31
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 31
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer 31
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 31
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe 31
Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. 31
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer 31
Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction 31
Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features 30
Management of stage III and IVa uterine cancer 30
Nomogram-based prediction of cervical dysplasia persistence/recurrence 30
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study 30
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 30
Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer 30
A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLO) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group 29
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy 29
Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 29
Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease 28
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study 28
Maternal ultrasound bone density in normal pregnancy 28
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 28
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 28
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial 28
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 27
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis 27
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity 27
Fertility sparing surgery in early stage epithelial ovarian cancer 27
Totale 4.159
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 7 4 3 6 3 0 3
2021/202219 2 0 0 2 0 0 0 2 1 2 4 6
2022/202387 13 2 7 13 2 8 0 11 16 9 5 1
2023/2024907 6 5 11 3 0 8 2 0 271 21 187 393
2024/20254.263 82 108 147 44 17 297 336 248 683 1.105 623 573
2025/20264.714 1.630 779 648 982 378 297 0 0 0 0 0 0
Totale 10.016